Bretylium

CARDIOVASCULAR SYSTEM

Key facts

Bretylium is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1986. DrugCentral lists 3 molecular targets, including ADRB1, ADRB2 and SLC6A2. Recorded indications include Life-Threatening Ventricular Tachycardia, Prevention of Ventricular Fibrillation, Ventricular arrhythmia and Ventricular fibrillation.

• Approval status: ofm (first approved 1986 by the FDA).
• Molecular targets: ADRB1, ADRB2 and SLC6A2 (3 listed in DrugCentral).
• Indications: Life-Threatening Ventricular Tachycardia, Prevention of Ventricular Fibrillation, Ventricular arrhythmia and Ventricular fibrillation.
• ATC code: C01BD02 (Antiarrhythmics, class III).
• Molecular formula: C11H17BrN; molecular weight 243.17 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Life-Threatening Ventricular Tachycardia
• Prevention of Ventricular Fibrillation
• Ventricular arrhythmia
• Ventricular fibrillation

Off-label uses (1)

• Cardiac arrest

Contraindications (6)

• Aortic valve stenosis
• Kidney disease
• Low cardiac output syndrome
• Orthostatic hypotension
• Pulmonary hypertension
• Sinus bradycardia

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
Beta-1 adrenergic receptor	ADRB1	unknown	—
Beta-2 adrenergic receptor	ADRB2	unknown	—
Sodium-dependent noradrenaline transporter	SLC6A2	substrate	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1986-03-06	FDA	—	INTL MEDICATION

ATC classification

ATC code	Therapeutic hierarchy
C01BD02	CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › ANTIARRHYTHMICS, CLASS I AND III › Antiarrhythmics, class III

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Bretylium is on its molecule page.

• Molecular formula: C₁₁H₁₇BrN
• Molecular weight: 243.17 g/mol
• CAS number: 61-75-6
• InChIKey: AAQOQKQBGPPFNS-UHFFFAOYSA-N
• PubChem CID: 2431

CC[N+](C)(C)CC1=C(Br)C=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Bretylium used for?

DrugCentral lists the following indications for Bretylium: Life-Threatening Ventricular Tachycardia, Prevention of Ventricular Fibrillation, Ventricular arrhythmia and Ventricular fibrillation.

How does Bretylium work?

Its molecular targets in DrugCentral include ADRB1, ADRB2 and SLC6A2 (substrate).

When was Bretylium first approved?

Bretylium was first approved by the FDA in 1986.

What is the chemical formula of Bretylium?

Bretylium has the molecular formula C11H17BrN and a molecular weight of 243.17 g/mol.

Sources

• DrugCentral drug card 394 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1095292 — compound record and bioactivity
• PubChem CID 2431 — chemical identifiers
• DrugBank DB01158 — drug record
• FDA UNII RZR75EQ2KJ — substance identity
• DailyMed: FDA labels for Bretylium — current prescribing information (label search)
• UniProt P08588 (ADRB1) — target protein
• UniProt P07550 (ADRB2) — target protein
• UniProt P23975 (SLC6A2) — target protein

How this page is built: methodology · editorial policy & corrections.